VitaDX signs a strategic partnership with the XPath group for the use of its VisioCyt® software solution
XPath, a group of medical specialists in pathological anatomy and cytology, a player in this medical specialty that has made... View Article
AbolerIS Pharma selected for the HealthTech For Care Innovation Award
The HealthTech For Care Innovation Award will be presented for the first time at the HealthTech Innovation Days on October... View Article
Valneva reports further positive phase 3 immunogenicity and the first heterologous booster tesults for its inactivated, adjuvanted COVID-19 vaccine VLA2001
Valneva, a specialty vaccine company, reported further positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine VLA2001. Additional readouts... View Article
New member | Rouen Normandy University
Rouen Normandy University, which employs more than 2500 persons, is a multidisciplinary university, hosting approximately 35,000 students, nearly a quarter... View Article
New member | University of Orléans
The University of Orléans is characterized by its multidisciplinary nature. It has 3 Training and Research Units, 1 university engineering... View Article
Valneva confirms WHO recommendations for its inactivated COVID-19 vaccine
Valneva, a specialty vaccine company, confirms that the World Health Organization (WHO) has issued recommendations for use of the Company’s... View Article
Framatome announces investment in Global Morpho Pharma for nuclear medicine development
Framatome announced that it acquired a minority stake in Global Morpho Pharma. With this investment, Framatome strengthens its activities serving... View Article
European Commission approves purchase agreement amendment for Valneva’s inactivated COVID-19 vaccine
European Commission to order 1.25 million doses of Valneva’s whole-virus COVID-19 vaccine VLA2001 in 2022 Valneva, a specialty vaccine company,... View Article
Focus on the Atlanpole Biotherapies 2022 General Assembly
ON TUESDAY 5th JULY, MORE THAN 150 PARTICIPANTS ATTENDED THE ATLANPOLE BIOTHERAPIES ANNUAL GENERAL ASSEMBLY. In addition to taking stock... View Article
OSE Immunotherapeutics appoints Alexis Vandier as Chief Executive Officer
OSE Immunotherapeutics is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately. Alexis Vandier brings... View Article